Problems of Clinical Use in Pediatric Drug and Countermeasures Analysis in China
- VernacularTitle:我国儿童药品在临床使用中存在的问题及对策分析
- Author:
Xueyun WANG
1
;
Weiwei SU
2
;
Hong DING
1
;
Wen GUO
3
;
Xuewei HUA
3
Author Information
1. School of Health Management，Anhui Medical University，Hefei 230032，China
2. Division of Drug Policy and Essential Drug System，National Health Commission of the People’s Republic of China，Beijing 100044，China
3. National Pharmaceutical Industry Informational Center，Shanghai 200040，China
- Publication Type:Journal Article
- Keywords:
Pediatric drug use;
Clinical use;
Problems;
Countermeasures
- From:
China Pharmacy
2019;30(2):149-153
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE： Te analyze the problems of clinical use in pediatric drug in China， and to put forward related countermeasures and suggestions. METHODS： Using “children” and “pediatrics” as retrieval words， registered drug information were retrieved from the website of China Food and Drug Administration； the data of pediatric drug use prescription was retrieved from hospital prescription system of 9 hospitals； all drug information were retrieved from national drug data management system； off-label drug use investigation and the literatures of pediatric drug use in medical institutions （5 representative third grade general medical institutions） were retrieved from CNKI and Wanfang database. General information and problems of pediatric drug use in China were investigated. RESULTS： A total of 170 009 items of registered drug information were retrieved， including 2 784 drug information items labeled with ”children” or ”pediatrics”， accounting for 1.64％；320 000 drug prescriptions from hospital prescription system of 9 hospitals covered 22 treatment areas involving 1 186 drugs and 51 dosage forms. Only 10％ suitable for children. The retrieval results of database showed that the incidence of children off-label drug use in outpatients prescriptions of 5 hospitals was in high level， mainly manifesting as without the information of pediatric drug use， hyper-indication drug use， hyper-dosage drug use. There were many problems in clinical pediatric drug use in China， such as less variety for children， single dosage form and specification， widespread off-label drug use， lack of scientific reference for drug use， difficulty in developing pediatric drug clinical trials， etc. CONCLUSIONS： Although the policies to protect children’s clinical drug use have been introduced in China， the problems facing children’s clinical drug use in China are still very serious. While further implementing relevant policies， it is necessary to establish a linkage management system led by government departments， with the full participation and mutual cooperation of society， enterprises， medical institutions and patients so as to guaratee the safety of pediatric drug use in clinic.
